Lilly Rises as Study Shows Diabetes Drug Cuts Cardiac Risk

Updated on

A diabetes drug sold by Eli Lilly & Co. and Boehringer Ingelheim GmbH lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes, compared with the standard of care alone.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.